Products for Research Use Only
RegisterLogin

Capmatinib

CAT: 0804-HY-13404-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-13404-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Capmatinib (INC280; INCB28060) is a potent, orally active, selective, and ATP competitive c-Met kinase inhibitor (IC50=0.13 nM) . Capmatinib can inhibit phosphorylation of c-MET as well as c-MET pathway downstream effectors such as ERK1/2, AKT, FAK, GAB1, and STAT3/5. Capmatinib potently inhibits c-MET-dependent tumor cell proliferation and migration and effectively induces apoptosis. Antitumor activity. Capmatinib is largely metabolized by CYP3A4 and aldehyde oxidase[1][2][3].
CAS Number
1029712-80-8
Product Name Alternative
INC280; INCB28060
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Apoptosis; c-Met/HGFR
Type
Reference compound
Related Pathways
Apoptosis; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/INCB28060.html
Purity
99.82
Solubility
DMSO : 5 mg/mL (ultrasonic; warming; heat to 60°C) |H2O : < 0.1 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
O=C(NC)C1=CC=C(C2=NN3C(N=C2)=NC=C3CC4=CC=C5N=CC=CC5=C4)C=C1F
Molecular Formula
C23H17FN6O
Molecular Weight
412.42
Precautions
H302, H315, H319, H335
References & Citations
[1]Liu X, et al. A novel kinase inhibitor, INCB28060, blocks c-MET-dependent signaling, neoplastic activities, and cross-talk with EGFR and HER-3. Clin Cancer Res. 2011 Nov 15;17 (22) :7127-38.|[2]Baltschukat S, et al. Capmatinib (INC280) Is Active Against Models of Non-Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation. Clin Cancer Res. 2019 May 15;25 (10) :3164-3175.|[3]Dhillon S. Capmatinib: First Approval. Drugs. 2020 Jul;80 (11) :1125-1131.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched

Alternative Products

CatalogName
B3005-5Capmatinib
BUP09131-01Capmatinib xHCl
CS-EO-02512Capmatinib D3
MBS3607865-01Capmatinib 2HCl
MBS3612843-01Capmatinib hydrochloride

Popular Products